Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	54337
Country	United States

Received	2020-01-21 16:44
Peer-Review Started	2020-01-21 16:45
To Make the First Decision
Return for Revision	2020-03-05 22:04
Revised	2020-05-16 03:43
Second Decision	2020-07-31 09:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-08-01 21:27
Articles in Press	2020-08-01 21:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-08-05 01:05
Publish the Manuscript Online	2020-08-12 09:10

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions
Manuscript Source	Invited Manuscript
All Author List	Sakti Chakrabarti, Carrie Y Peterson, Deepika Sriram and Amit Mahipal
Funding Agency and Grant Number
Corresponding Author	Sakti Chakrabarti, MD, Associate Professor, Division of Hematology/Oncology, Medical College of Wisconsin, No. 8701, Watertown Plank Road, Milwaukee, WI 53226, United States. schakrabarti@mcw.edu
Key Words	Adjuvant; Circulating tumor DNA; Immunoscore; Minimally invasive; Neoadjuvant; FOxTROT
Core Tip	Although the majority of patients with colon cancer are diagnosed in an early stage, cancer recurrence after initial curative therapy is frequent, underscoring the need for novel approaches. The challenges in the current treatment paradigm include the lack of precise patient selection tools for adjuvant therapy, disabling toxicities, and modest efficacy of the adjuvant therapies. Herein we provide a contemporaneous appraisal of the early stage colon cancer treatment and discuss how evolving technologies, including circulating tumor DNA, can potentially transform the standard of care.
Publish Date	2020-08-12 09:10
Citation	Chakrabarti S, Peterson CY, Sriram D, Mahipal A. Early stage colon cancer: Current treatment standards, evolving paradigms, future directions. World J Gastrointest Oncol 2020; 12(8): 808-832
URL	https://www.wjgnet.com/1948-5204/full/v12/i8/808.htm
DOI	https://dx.doi.org/10.4251/wjgo.v12.i8.808

Full Article (PDF)	WJGO-12-808.pdf
Full Article (Word)	WJGO-12-808.docx
Manuscript File	54337-Review.docx
Answering Reviewers	54337-Answering reviewers.pdf
Audio Core Tip	54337-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	54337-Conflict-of-interest statement.pdf
Copyright License Agreement	54337-Copyright license agreement.pdf
Peer-review Report	54337-Peer-review(s).pdf
Scientific Misconduct Check	54337-Scientific misconduct check.pdf
Scientific Editor Work List	54337-Scientific editor work list.pdf